Edesa Biotech director granted 19,000 RSUs

Edesa Biotech director Charles V. Olson received an equity grant of 19,000 common shares on May 27, 2026.

Accepted by SEC EDGAR 05/29/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Edesa Biotech director Charles V. Olson received an equity grant of 19,000 common shares on May 27, 2026. The shares were awarded at a price of $0.00 per share as a compensation grant, not an open market purchase. Following this transaction, Olson directly holds 30,000 common shares. According to the grant terms, these restricted share units will vest in equal portions over twelve months starting from the grant date, meaning the award converts into fully owned shares gradually over one year.

Insider Trade Summary

Grant/Award: 19,000 shares

Grant/Award 1 txn

Insider Olson Charles V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	19,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 30,000 shares (Direct)

Footnotes (1)

1. F1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Key Figures

Equity grant size: 19,000 shares Grant price: $0.00 per share Holdings after grant: 30,000 shares +1 more

4 metrics

Equity grant size 19,000 shares Restricted share units granted May 27, 2026

Grant price $0.00 per share Compensation award, not open market purchase

Holdings after grant 30,000 shares Total common shares directly held after transaction

Vesting period 12 months RSUs vest in equal monthly portions from grant date

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, vesting

3 terms

restricted share units financial

"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions"

vesting financial

"which shall vest in equal proportions over twelve (12) months, commencing on the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edesa Biotech (EDSA) report for Charles V. Olson?

Edesa Biotech reported that director Charles V. Olson received a grant of 19,000 common shares as compensation. The award was made at $0.00 per share and increased his direct holdings to 30,000 common shares after the transaction.

Was the Edesa Biotech (EDSA) Form 4 transaction a stock purchase or a grant?

The Form 4 discloses a grant of 19,000 restricted share units to director Charles V. Olson, not an open market stock purchase. The transaction code “A” indicates a grant, award, or other acquisition related to compensation, issued at $0.00 per share.

How do the granted Edesa Biotech (EDSA) shares vest for Charles V. Olson?

The 19,000 restricted share units granted to Charles V. Olson vest in equal portions over twelve months. Vesting begins on the grant date, so the award converts into fully owned shares gradually each month during the one-year vesting schedule.

What are Charles V. Olson’s Edesa Biotech (EDSA) share holdings after this Form 4?

After the reported grant, Charles V. Olson holds 30,000 Edesa Biotech common shares directly. This figure includes the 19,000-share compensation grant reported in the Form 4 and represents his total direct ownership following the transaction.

Under which plan were the Edesa Biotech (EDSA) restricted share units granted?

The 19,000 restricted share units granted to Charles V. Olson were issued under Edesa Biotech’s 2019 Equity Incentive Compensation Plan. This plan provides equity-based awards to directors and other participants as part of the company’s compensation structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olson Charles V

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/27/2026		A		19,000(1)	A	$0(1)	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

	/s/ Peter J. Weiler, Attorney-in-Fact for Charles V. Olson	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)